Pharmacovigilance Software Market (2026-2036)
The global Pharmacovigilance Software Market was valued at USD 1,260.0 million in 2025. This market is expected to reach USD 3,398.1 million by 2036 from an estimated USD 1,397.3 million in 2026, registering a CAGR of 9.3% during the forecast period (2026-2036).
- Published
- Jun 2026
- Pages
- 306
- Format
- PDF + Excel
- Report ID
- MRHC - 1042043
- Base year
- 2025
- 2025 · BASELINE
- $1.26B
- 2036
- $3.40B
- CAGR 2026–2036
- 9.3%
2025 baseline · 2026–2036 forecast at 9.3% CAGR · hover a bar for the value
Key highlights
The global Pharmacovigilance Software Market is projected to reach USD 3, 398.1 million by 2036 from an estimated USD 1,397.3 million in 2026, at a CAGR of 9.3%, with annual growth easing from about 11% in 2026 to about 7% by 2036 as the market matures.
The FDA has required the ICH E2B(R3) standard for premarketing (IND) safety reports since April 1, 2026, and for postmarketing safety reports submitted through its Electronic Submissions Gateway Next Generation from October 1, 2026, while EudraVigilance processed 1,765,581 individual case safety reports in 2025.
By functionality, the adverse event case management segment is expected to account for the largest share of 41.3% of the market in 2026, while the safety analytics & AI automation segment is projected to register the highest CAGR of 13.1%, raising its share from 12.0% to 16.9% by 2036.
By deployment mode, the cloud-based segment is expected to account for the larger share of 69.5% of the market in 2026 and to register the higher CAGR of 11.5%, reaching 84.6% of the market by 2036 and accounting for about 95% of total market growth.
By end user, the pharmaceutical companies segment is expected to account for the largest share of 51.2% of the market in 2026, while the biotechnology companies and CROs & PV outsourcing providers segments are projected to register the highest CAGRs of 10.5% each.
North America is expected to account for the largest market share of 41.0% in 2026, while Asia-Pacific is projected to register the highest CAGR of 10.9% during the forecast period, led by India, the fastest-growing country market at 13.5%.
Report summary
| Particulars | Details |
|---|---|
| Forecast Period | 2026-2036 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| CAGR (Value) | 9.3% |
| Format | PDF, Excel & Cloud Portal · 306 pages |
| Market Size (Value) in 2026 | USD 1,397.3 Million |
| Market Size (Value) in 2036 | USD 3,398.1 Million |
| Segments Covered | By Functionality: Adverse Event Case Management, Signal Detection & Management, Aggregate & Periodic Reporting, Risk Management, Literature & Social Media Monitoring, Safety Analytics & AI Automation. By Component: Software, Services. By Deployment Mode: Cloud-Based, On-Premises. By Organization Size: Large Enterprises, Small & Mid-Sized Enterprises. By End User: Pharmaceutical Companies, Biotechnology Companies, CROs & PV Outsourcing Providers, Medical Device Manufacturers, Regulatory Authorities & Others. |
| Countries Covered | North America: U.S., Canada. Europe: Germany, U.K., France, Switzerland, Italy, Spain, Netherlands, Nordic Countries, Belgium, Rest of Europe. Asia-Pacific: Japan, China, India, South Korea, Australia, Singapore, Rest of Asia-Pacific. Latin America: Brazil, Mexico, Rest of Latin America. Middle East & Africa: Israel, Saudi Arabia, UAE, South Africa, Rest of Middle East & Africa. |
| Key Companies | Oracle, Veeva Systems, ArisGlobal, IQVIA, Ennov, AB Cube, RxLogix, Qinecsa Solutions, Sarjen Systems, Clinevo Technologies, Cloudbyz, and Biologit. |
Report overview
Segments covered: functionality, component, deployment mode, organization size, end user.
The growth of this market is mainly driven by expanding regulatory reporting requirements, rising adverse event case volumes, the growth of biotechnology and new product pipelines, and the migration of safety systems to the cloud. However, high implementation and validation costs and legacy system lock-in and migration complexity restrain the growth of this market.
Furthermore, AI-driven automation of case processing, demand from small and mid-sized biopharmaceutical companies, and the development of pharmacovigilance (PV) systems in emerging markets are expected to offer growth opportunities for the stakeholders in this market. However, the validation and regulatory acceptance of AI, data privacy and residency requirements, and shortages of skilled PV and technology staff remain major challenges impacting the growth of this market. Additionally, generative and agentic AI in safety operations, the consolidation of safety, regulatory, and quality platforms, and the integration of real-world data into signal detection are prominent trends in this market.
The Pharmacovigilance Software Market comprises software and related services used to collect, process, assess, and report adverse events and to monitor the safety of medicinal products and medical devices throughout their lifecycle. The market covers adverse event case management, signal detection and management, aggregate and periodic reporting, risk management, literature and social media monitoring, and safety analytics and AI automation, delivered as software and services through cloud-based and on-premises deployment to large enterprises and small and mid-sized enterprises, including pharmaceutical companies, biotechnology companies, CROs and PV outsourcing providers, medical device manufacturers, and regulatory authorities.
Every marketing authorization holder must collect, assess, and report adverse events to regulators within defined timelines, and these obligations apply for the entire life of each product. EudraVigilance held 31,253,245 individual case safety reports by the end of 2025, and ArisGlobal reported that its LifeSphere platform processes more than 12 million safety cases a year for its customers. Because manual case processing is labor-intensive, companies rely on validated software to manage intake, coding, assessment, and submission.
Regulatory change is a major source of near-term demand. The FDA transition to the ICH E2B(R3) standard in 2026 follows the EU transition completed in June 2022, and many companies are combining the required upgrade with a move to cloud-based platforms or the consolidation of multiple safety databases. At the same time, vendors are introducing generative and agentic AI for case intake, coding, and narrative writing.
The market is therefore shifting from on-premises systems to cloud subscriptions, from core case processing toward signal detection, analytics, and AI, and from large pharmaceutical companies toward biotechnology companies, CROs, and small and mid-sized buyers. Platform consolidation, highlighted by the agreement of Dassault Systèmes in July 2026 to acquire ArisGlobal for about USD 1.8 billion, is creating larger vendors that combine safety with clinical, regulatory, and quality software.
Market dynamics
12 factors across 4 forcesExpanding Regulatory Reporting Requirements
Expanding regulatory reporting requirements are the strongest factor driving the Pharmacovigilance Software Market, because every marketing authorization holder must meet defined timelines for expedited and periodic safety reporting. The transition to the ICH E2B(R3) standard is the most important near-term change: the FDA has required it for IND safety reports since April 1, 2026, and for postmarketing reports from October 1, 2026, while it has been mandatory for EudraVigilance reporting since June 30, 2022. According to the FDA, 25 companies had adopted the new submission format by February 2025, which indicates that many companies were still upgrading their systems ahead of the deadlines.
Rising Adverse Event Case Volumes
Adverse event case volumes continue to grow with larger product portfolios, broader approvals, and more sources of safety information. EudraVigilance held 31,253,245 individual case safety reports by December 31, 2025, and processed 1,765,581 reports in 2025, while ArisGlobal reported that its LifeSphere platform processes more than 12 million safety cases a year. Because manual processing is expensive, companies are investing in software that automates intake, coding, duplicate detection, and reporting.
Growth of Biotechnology and New Product Pipelines
Biotechnology companies developing biologics, cell and gene therapies, and other novel products need safety systems from the start of clinical development, and many build their own safety functions as products approach approval. Novel therapies often carry complex safety profiles that require close monitoring, risk management plans, and long-term follow-up. These companies typically prefer cloud-based software that can be deployed quickly without large internal IT teams, creating a steady flow of new implementations.
Migration of Safety Systems to the Cloud
The migration of safety systems from on-premises installations to cloud-based platforms is reshaping how companies buy and use PV software. Cloud platforms reduce the burden of infrastructure management, upgrade validation, and maintenance, because vendors deliver regular validated releases. Vendors such as Veeva, which launched Vault Safety in 2019, and ArisGlobal, with its LifeSphere platform, are encouraging customers with legacy systems to move to cloud-native platforms, converting one-time licence purchases into recurring subscriptions.
Table of contents
13 chapters · 224 sections · 306 pages · click to expandSegmental analysis
| Segment | Largest share (2026) | Fastest growth (2026–2036) |
|---|---|---|
| By Functionality | Adverse Event Case Management | Safety Analytics & AI Automation |
| By Component | Software | — |
| By Deployment Mode | Cloud deployment | Rapid growth of this |
| By Organization Size | Large enterprises | Rapid growth of this |
| By End User | Pharmaceutical Companies | — |
By Functionality
- The Adverse Event Case Management segment is expected to account for the largest share of 41.3% of the market.
- The large share of this segment is mainly due to the fact that case management is the core regulatory requirement for every marketing authorization holder, CRO, and device manufacturer, and to the upgrades driven by the FDA transition to E2B(R3) in 2026.
- The segment is also projected to add USD 580.4 million between 2026 and 2036, the largest absolute increase among functionalities, although its share declines to 34.1% as automation lowers the cost of each case.
- However, the Safety Analytics & AI Automation segment is projected to register the highest CAGR of 13.1% during the forecast period, raising its share from 12.0% of the market in 2026 to 16.9% in 2036.
- The rapid growth of this segment is driven by the automation of case processing and the adoption of generative and agentic AI, such as ArisGlobal NavaX and the safety AI agents of Veeva, and by pricing models linked to automation and case volumes.
- Signal detection & management and literature & social media monitoring also grow faster than the market, at 10.6% each, supported by real-world data integration and automated literature screening.
By Component
- The Software segment is expected to account for the larger share of 69.0% of the market.
- The large share of this segment is mainly due to the shift from perpetual licences to cloud subscriptions, the expansion of customers into additional modules, and the concentration of revenue among large platform vendors such as Oracle, Veeva, ArisGlobal, and IQVIA.
- Software accounts for the highest shares of national markets in Israel, the U.S., Switzerland, and the Nordic countries, where cloud adoption is high and deployments are mature.
- The Software segment is also projected to register the higher CAGR of 9.7% during the forecast period, rising to 71.6% of the market by 2036 and accounting for about 73.5% of total market growth.
- The growth of this segment is driven by cloud subscriptions, AI modules, and pre-configured, pre-validated solutions that require fewer services.
- Services still add USD 530.8 million over the forecast period, supported by migrations linked to E2B(R3) and platform changes, and remain most important in emerging markets such as India and South Africa.
By Deployment Mode
- The Cloud-Based segment is expected to account for the larger share of 69.5% of the market.
- The large share of this segment is mainly due to the cloud-native platforms of leading vendors, such as Veeva Vault Safety and ArisGlobal LifeSphere, which shift infrastructure management and much of the validation of upgrades to the vendor, and to the preference of biotechnology companies for SaaS from the start.
- Cloud deployment accounts for the highest shares of national markets in the U.S., the U.K., Singapore, and Israel.
- The Cloud-Based segment is also projected to register the higher CAGR of 11.5% during the forecast period, rising to 84.6% of the market by 2036 and accounting for about 95% of total market growth.
- The rapid growth of this segment is driven by the migration of legacy systems to SaaS platforms, new deployments by biotechnology companies, and the delivery of AI capabilities through regular cloud releases.
- On-premises deployment, by contrast, is projected to grow at a CAGR of only 2.1%, sustained mainly by data residency rules in markets such as Saudi Arabia and China.
By Organization Size
- The Large Enterprises segment is expected to account for the larger share of 72.8% of the market.
- The large share of this segment is mainly due to the global multi-module platforms, complex integrations, and high case volumes of large pharmaceutical, biotechnology, and device companies and service providers, and to their investment in AI automation and the consolidation of multiple safety databases into single global platforms.
- Large enterprises account for the highest shares of national markets in Japan, Mexico, and Brazil.
- However, the Small & Mid-Sized Enterprises segment is projected to register the higher CAGR of 11.3% during the forecast period, raising its share from 27.2% of the market in 2026 to 32.6% in 2036.
- The rapid growth of this segment is driven by the expansion of biotechnology pipelines, the move of commercial-stage companies to in-house safety operations, and the availability of affordable pre-configured cloud solutions with subscription pricing.
- SMEs account for the highest shares of national markets in Israel, the U.S., and Australia, where dense biotechnology sectors create many smaller buyers.
By End User
- The Pharmaceutical Companies segment is expected to account for the largest share of 51.2% of the market.
- The large share of this segment is mainly due to the global ICSR, periodic, signal, and risk management obligations of pharmaceutical companies, their large product portfolios and case volumes, and their enterprise multi-module platforms.
- The segment is projected to add USD 847.9 million between 2026 and 2036, the largest increase among end users.
- However, the Biotechnology Companies and CROs & PV Outsourcing Providers segments are projected to register the highest CAGRs of 10.5% each during the forecast period.
- The growth of the biotechnology segment is driven by expanding pipelines of novel therapies and the move of commercial-stage companies from CRO-hosted systems to their own safety databases, while the growth of the CRO segment is driven by the continued outsourcing of PV operations and investment in multi-tenant platforms and automation, as shown by the selection of ArisGlobal LifeSphere MultiVigilance by the Japanese CRO EPS Corporation in December 2025.
- Medical device manufacturers also grow faster than the market, at 10.4%.
Geographic analysis
North America
Largest shareIn 2026, North America is expected to account for the largest share of 41.0% of the global Pharmacovigilance Software Market. The large share of North America is attributed to the size of the U.S. pharmaceutical and biotechnology industries, the FDA transition to E2B(R3) for premarketing and postmarketing safety reports in 2026, and the early adoption of cloud and AI capabilities. The U.S. is the largest country market in the world, while Canada is the faster-growing market in the region, at a CAGR of 8.8%. North America
Europe
Europe is expected to account for a share of 28.9% of the market in 2026, supported by the EU Good Pharmacovigilance Practices framework, the mandatory use of E2B(R3) for EudraVigilance reporting since June 2022, and large research-based pharmaceutical companies in Switzerland, Germany, the U.K., and France. The U.K. is the largest market in the region, slightly ahead of Germany, while Spain is the fastest-growing of the individually analysed countries. Europe
Asia-Pacific
Fastest growthHowever, Asia-Pacific is projected to register the highest CAGR of 10.9% during the forecast period. The rapid growth of this region is attributed to the strengthening of PV requirements in China, which joined the ICH in 2017, the growth of generics manufacturing, and the role of India as a global PV outsourcing hub. India is the fastest-growing country market in the world, at a CAGR of 13.5%, while Japan is the largest market in the region and the second-largest country market in the world. Asia-Pacific
Middle East & Africa
The Middle East & Africa is expected to account for a share of 1.7% of the market in 2026, supported by the strengthening of national PV systems and pharmaceutical localization in the Gulf. Israel is the largest market in the region, driven by its biotechnology sector and high cloud readiness, while Saudi Arabia is the fastest-growing, at a CAGR of 11.9%. Middle East & Africa
Latin America
Latin America is expected to account for a share of 1.6% of the market in 2026, with demand led by multinational affiliates and large domestic pharmaceutical companies. Brazil is the largest market in the region, while Mexico is the fastest-growing, at a CAGR of 10.7%. Latin America
Competitive landscape
The global Pharmacovigilance Software Market is led by a small group of platform vendors, alongside specialists that compete in specific functions and regions. In 2025, Oracle held an estimated 19.8% share, followed by Veeva Systems (9.5%), ArisGlobal (7.9%), IQVIA (7.1%), Qinecsa Solutions (2.5%), and Ennov (2.4%), while other players accounted for 50.8%. Competition centers on cloud delivery, AI capabilities, platform breadth, and migration support for customers with legacy systems.
Between January 2024 and July 2026, the 12 key players profiled in the report announced 70 strategic developments, comprising 27 product launches, 27 agreements and contracts, 8 partnerships, 4 acquisitions, 2 expansions, and 2 investments. Major examples include the agentic AI launches of ArisGlobal, Veeva, Oracle, and RxLogix, the go-live of UCB on the full Veeva Safety Suite in June 2026, and the agreement of Dassault Systèmes to acquire ArisGlobal in July 2026.
The report provides a comprehensive competitive assessment of the leading companies operating in the global Pharmacovigilance Software Market. The key players profiled in the report include Oracle Corporation (U.S.), Veeva Systems Inc. (U.S.), ArisGlobal LLC (U.S.), IQVIA Holdings Inc. (U.S.), Ennov (France), AB Cube (France), RxLogix Corporation (U.S.), Qinecsa Solutions (U.K.), Sarjen Systems Pvt. Ltd. (India), Clinevo Technologies (India), Cloudbyz (U.S.), and Biologit (Ireland).
- Oracle
- Veeva Systems
- ArisGlobal
- IQVIA
- Ennov, AB Cube
- RxLogix
- Qinecsa Solutions
- Sarjen Systems
- Clinevo Technologies
- Cloudbyz
- Biologit
Expert perspectives
Pharmacovigilance software is moving from a compliance cost to a platform for automated, data-driven safety operations. Regulatory deadlines such as the FDA transition to E2B(R3) are prompting upgrades and migrations, while cloud platforms and AI are changing how safety cases are processed and how signals are detected.
Three structural shifts are expected to shape the market through 2036. First, cloud deployment becomes almost universal, accounting for about 95% of market growth. Second, spending moves from core case processing toward safety analytics, AI automation, and signal detection, as automation lowers the cost of each case. Third, demand broadens from large pharmaceutical companies to biotechnology companies, CROs, and small and mid-sized buyers, and from North America and Europe toward Asia-Pacific.
For companies planning entry or expansion, the most attractive positions over the forecast period are likely to be found in validated AI automation for case processing, signal detection with real-world data, pre-configured cloud solutions for SMEs, multi-tenant platforms for CROs, and early positions in fast-growing markets such as India, China, and Saudi Arabia. The principal risks are the validation and regulatory acceptance of AI, data residency rules, legacy lock-in, and continued platform consolidation.
Customer perspectives
Insights gathered during primary interviews with heads of drug safety at pharmaceutical and biotechnology companies, PV operations leaders at CROs, and executives at PV software vendors highlight where priorities are shifting. The following perspectives reflect recurring themes raised across these discussions.
“This reflects how regulatory deadlines and automation are driving platform migrations at large enterprises.”
“This indicates why SMEs and biotechnology companies favor pre-configured cloud solutions.”
“This highlights the role of CROs as a fast-growing source of demand for automated PV software.”
Frequently asked questions
The global Pharmacovigilance Software Market is estimated at USD 1,397.3 million in 2026.
Cite this report
Meticulous Research. (2026). Pharmacovigilance Software Market - Global Opportunity Analysis and Industry Forecast (2026-2036) (Report No. MRHC - 1042043). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/pharmacovigilance-software-market-6726